Davis M J, Dawes P T, Beswick E, Lewin I V, Stanworth D R
Staffordshire Rheumatology Centre, Haywood Hospital, Burslem, Stoke-on-Trent UK.
Br J Rheumatol. 1989 Oct;28(5):410-3. doi: 10.1093/rheumatology/28.5.410.
Serum levels of immunoglobulin A (IgA) and the complex immunoglobulin A-alpha 1 antitrypsin (IgA-alpha 1AT) were measured at the commencement and after 3 months of a double-blind, placebo-controlled trial of sulphasalazine (SAS) in patients with active ankylosing spondylitis (AS). Twenty-eight patients were evaluated, 15 on sulphasalazine, 13 on placebo. Significant falls were seen in both IgA (p less than 0.01) and IgA-alpha 1AT (p less than 0.001) in the actively treated patients. In addition, significant improvement in clinical and laboratory measures of disease were observed. It is concluded that SAS is effective in AS and modulates the immune response.
在一项针对活动性强直性脊柱炎（AS）患者的柳氮磺胺吡啶（SAS）双盲、安慰剂对照试验开始时及3个月后，测量了免疫球蛋白A（IgA）和复合免疫球蛋白A-α1抗胰蛋白酶（IgA-α1AT）的血清水平。对28例患者进行了评估，其中15例服用柳氮磺胺吡啶，13例服用安慰剂。积极治疗的患者中，IgA（p<0.01）和IgA-α1AT（p<0.001）均显著下降。此外，观察到疾病的临床和实验室指标有显著改善。得出结论，柳氮磺胺吡啶对强直性脊柱炎有效并可调节免疫反应。
